PDCD1 and non-small cell lung carcinoma: The 5-year OS rate was 13.4% with nivolumab and 2.6% with docetaxel; this finding is particularly interesting considering that these studies are those with the longest follow-up time among randomized phase 3 trials testing a PD-1 inhibitor in previously treated advanced NSCLC.